Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Drug Profile

Plozasiran - Arrowhead Pharmaceuticals

Alternative Names: ARO-APOC3

Latest Information Update: 31 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Class Antihyperlipidaemics; Small interfering RNA
  • Mechanism of Action APOC3 protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperlipoproteinaemia type I
  • Phase III Hypertriglyceridaemia
  • Phase II Dyslipidaemias

Most Recent Events

  • 31 Dec 2024 Updated data from a phase II extension trial in Dyslipidemia presented at the American Heart Association Scientific Sessions 2024 (AHA-2024)
  • 29 Nov 2024 Phase-III clinical trials in Hypertriglyceridaemia (Treatment-experienced) in France, Germany, Latvia, Latvia, Lithuania, New Zealand (SC) (NCT06347016)
  • 29 Nov 2024 Arrowhead Pharmaceuticals initiates a Phase-III clinical trials in Hypertriglyceridaemia (Treatment-experienced) in USA, Australia, Bulgaria, Canada, Czech Republic, Hungary, Poland, Slovakia and UK (SC) (NCT06347016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days